Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rahul Iyer
Observed name:
Rahul N. Iyer
Institution:
Cipla (India)
Observed institution:
Cipla (India)
ORCID:
0000-0002-1513-4357
Observed ORCID:
0000-0002-1513-4357
OpenAlex ID:
A5103043474
Inhaled Insulin Decoded: Dispelling Myths and Presenting Clinical Evidence
2025
·
Jothydev Kesavadev
, Hemant P Thacker
, et al.
·
Cureus
·
3
PDF
Current Practices and Perspectives of Clinicians on Glucose Monitoring in Indian Patients with Type 2 Diabetes Mellitus
2025
·
Bharat Saboo
, Pramila Kalra
, et al.
·
International Journal of Diabetes and Technology
·
1
Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study]
2025
·
Rakesh Sahay
, Anil Bhansali
, et al.
·
Drugs - Real World Outcomes
·
1
PDF
Postprandial Matters: Identifying Multifactorial Determinants and Rethinking Glucose Monitoring
2026
·
Subhash K. Wangnoo
, Ashok K. Das
, et al.
·
Journal of Diabetology
Bridging the gap: understanding barriers to injectable insulin in India
2026
·
Banshi Saboo
, Anuj Maheshwari
, et al.
·
International Journal of Diabetes in Developing Countries
Understanding the Preference of a Dipeptidyl Peptidase-4 Inhibitor and its Combination Therapy in Type 2 Diabetes Mellitus among Indian Clinicians
2024
·
K. V. S. Hari Kumar
, Shreerang Godbole
, et al.
·
International Journal of Diabetes and Technology
Survey to Specify SGLT2 Inhibitor Choice in T2DM Management
2022
·
Samit Ghosal
, Radhika M. Joshi
, et al.
·
Clinical Diabetology
Show more works
View as search
Works count:
7
Citation count:
5
H-index:
1
I10-index:
Year
Topic
Type
